AFP and neoplasm: Given these findings, AFP-L3 and DCP may also play a role in liver transplant candidate selection since patients with high likelihood of recurrence may not derive the most benefit from liver transplant and better identify aggressive tumor biology that results in cancer progression despite LRT or other neoadjuvant therapies while on the transplant waitlist.